The launch of Probi’s postbiotic version of Lacticaseibacillus rhamnosus 271, Rham271h™ (DSM 6594), represents a key milestone for the company and reflects accelerating demand for comprehensive microbiome solutions with the possibility of creating a stronger footprint in the functional food and beverage category.
Delivering health benefits in functional food and beverage formats presents challenges, particularly in maintaining the stability and viability of live probiotics. Postbiotics address this need by offering improved stability, broad ingredient compatibility, and greater formulation flexibility.
Introducing postbiotic Rham271h™ for immune support
The launch of Rham 271h™ marks a significant step in Probi’s expansion beyond probiotic solutions. Derived from Lacticaseibacillus rhamnosus 271 (DMS 6594), the inactivated strain retains biological activity while offering enhanced stability including pH, heat and shelf stability in formulations. In-vitro studies furthermore demonstrate that Rham271h™ maintains the immune-modulating properties previously established in the probiotic strain, Rham271.
Studies have shown that the postbiotic strain significantly increases the anti-inflammatory cytokine IL-10, while supporting gut barrier integrity and balanced immune responses linked to inflammation.
“With a minimum effective daily dose of 10 billion TFU, Rham271h ™ provides a stable and predictable alternative to live probiotics,” says Anita Johansen, CEO, Probi. “This makes it ideal for food and beverage applications where viability, shelf life, and formulation constraints are critical.” Rham271h™ is also Non-GMO, Gluten-Free, Halal-certified, and the strain is included on the QPS list.
“Rham 271h™ represents an important addition to our portfolio,” Johansen added. “It allows us to offer our customers greater flexibility in product development, reflects Probi’s commitment to advancing innovation in microbiome science and builds a strong scientific foundation for our strains.”
As a leader in microbiome science, Probi delivers scientifically validated biotic solutions across a complete portfolio of prebiotics, probiotics, synbiotics, and postbiotics. Supported by a vertically integrated supply chain, the company provides high-quality, reliable solutions designed to help partners with innovative, science-driven products that meet evolving consumer needs.
With postbiotics poised for double-digit growth through 2030, the introduction of Rham271h™ opens new opportunities for manufacturers to create stable, effective, and consumer-friendly health solutions across functional food, beverage, and dietary supplement categories.
Visit Probi at Vitafoods, booth 3A88, or to schedule a press interview, click here.
